Covid-19 levels in the United States are high and rising, flu season is approaching quickly and RSV cases are already ...

We are stronger when we are all protected against respiratory diseases,” said Dr. Tomas Aragon, public health officer for ...

Forecasts suggest respiratory infections will be similar to last year's season. Vaccination rates will be a factor in the ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...

During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest ...

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...

GSK’s ex-head of vaccines says its blockbuster jab for a flu-like virus that spreads in the autumn and winter is too ...

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

There are multiple options available; mRNA vaccines from Moderna and Pfizer were updated ... what has typically been the height of the respiratory virus season. But COVID-19 is circulating at ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its 2024 Investor Day. While these events are often catalysts for stock, ...